Icahn School of Medicine at Mount Sinai (ISMMS) - The Mount Sinai Hospital (MSH)
Icahn School of Medicine at Mount Sinai (ISMMS) - The Mount Sinai Hospital (MSH)
New York, New York, United States3 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease | Crohn disease, Digestive System Diseases, digestive system disorder, gastroenteritis, inflammatory bowel disease, intestinal disorder | Recruiting | Phase 2 | 2026-09-25 | NCT06233461 | |
| A Study to Learn How Well Dupilumab Works in Adult and Adolescent Participants With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis and the Side Effects it May Have | Digestive System Diseases, Eosinophilia, Eosinophilic enteropathy, Hemic and Lymphatic Diseases, Hypersensitivity, Immediate, digestive system disorder, eosinophilic esophagitis, eosinophilic gastroenteritis, esophageal disorder, esophagitis, gastroenteritis, hematologic disorder, immune system disorder, leukocyte disorder | Active, not recruiting | Phase 2 | 2026-07-01 | NCT05831176 | |
| A Study to Evaluate the Safety (Compared to Iron Sucrose), Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects With Chronic Kidney Disease (CKD) | Anemia, Hypochromic, Chronic Disease, Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Hemic and Lymphatic Diseases, Iron Deficiencies, Male Urogenital Diseases, Nutritional and Metabolic Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Urogenital Diseases, anemia, chronic renal failure syndrome, hematologic disorder, iron deficiency anemia, iron metabolism disease, kidney disorder, kidney failure, metabolic disease, urinary system disorder | Recruiting | Phase 3 | 2026-04-17 | NCT03619850 |